Abstract CT156: Phase 1 dose-optimization study evaluating the safety of ginisortamab (UCB6114), an anti-gremlin-1 monoclonal antibody (mAb) with first-in-class potential, as monotherapy in advanced solid tumors
Year: 2025
Type: conference-abstract
Source: Cancer Research
Institutions: King's College London, Guy's and St Thomas' NHS Foundation Trust, Medical University of South Carolina, MUSC Hollings Cancer Center, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Institute of Cancer Research, University of Manchester, The Christie NHS Foundation Trust, University of Southern California, Beatson West of Scotland Cancer Centre, University of Glasgow, UCB Pharma (United Kingdom), University of Oxford, Oxford University Hospitals NHS Trust
Language: English
Topic: TGF-β signaling in diseases
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4409821964